|
Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T. |
|
|
Consulting or Advisory Role - AstraZeneca; AVEO; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Merck; Novartis; Pfizer; QED Therapeutics; Sanofi; Seattle Genetics/Astellas |
Research Funding - Agensys (Inst); Aravive (Inst); Aveo (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Sanofi |
|
|
|
Honoraria - BMS; Tecnofarma; Tecnofarma |
Consulting or Advisory Role - Asofarma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Gilead Sciences; Janssen Oncology; Merck; MSD; MSD Oncology; Novartis; Novartis; Pfizer |
Speakers' Bureau - Asofarma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Ipsen; Janssen Oncology; Medicamenta; Merck; MSD Oncology; Pfizer; Tecnofarma |
Research Funding - Janssen Oncology (Inst); Pfizer |
Expert Testimony - Asofarma |
Travel, Accommodations, Expenses - Asofarma; Bristol-Myers Squibb (Mexico); Janssen-Cilag; MSD Oncology; Pfizer |
Other Relationship - Sanofi |
|
|
|
|
|
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche |
|
Yamil Alonso Lopez Chuken |
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb/Roche; GlaxoSmithKline; Janssen Oncology; Merck Serono; MSD Oncology; Novartis |
Honoraria - Astellas Pharma; Roche |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen; Merck; Pfizer; Zodiac Pharma |
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology |
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen Oncology; Merck; Pfizer; Zodiac Pharma |
Expert Testimony - Astellas Pharma; Bayer |
Travel, Accommodations, Expenses - Janssen Oncology; Zodiac Pharma |
|
|
Research Funding - Bristol-Myers Squibb; Lilly; MSD; Syneos Health |
|
|
Consulting or Advisory Role - AstraZeneca; BMS; MSD Oncology; Novartis; Roche/Genentech |
Speakers' Bureau - AstraZeneca; BMS; MSD Oncology; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex |
|
Eduardo Patricio Yanez Ruiz |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelx; Janssen; Merck Serono; MSD Oncology; Pfizer |
Travel, Accommodations, Expenses - Ipsen; Janssen |
|
|
Travel, Accommodations, Expenses - Bayer Schering Pharma; Merck Serono; MSD Oncology; Pfizer |
|
|
Employment - Bristol-Myers Squibb |
Leadership - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
Patents, Royalties, Other Intellectual Property - Rutgers Cancer Institute of New Jersey (I) |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer |